a user’s risk for Parkinson’s Disease, it was naturally seen as big
validation for its crowdsourced and community-driven approach togenetic research.With its patent representing both a validation of its research and modeland a potential new revenue stream), 23andMe now wants to doubledown on patient and community-driven research. And what better wayto follow your first patent than with your first acquisition? On Tuesday,the company officially announced that it is scooping up the four-year-oldCureTogether,a similarly-focused startup that aims to give people
the tools they need to create their own research studies, learn about theirhealth, and connect with experts and others who suffer from similarconditions.Launched in 2008, CureTogether began simply as a way to help peoplewho live with chronic pain fight depression and connect with acommunity. Starting with three conditions, the startup quickly expandedits scope and today has over 25,000 members, who have shared overfour million data points on 576 medical conditions.
While the terms of the deal were not disclosed, CureTogether’s founders
Daniel Reda and Alexandra Carmichael will be joining the team, alongwith, presumably, the startups user base. For 23andMe, the acquisitionadds a whole heap of new c
ommunity resources that will improve users’
ability to share information, talk about symptoms, and comparetreatment efficacies as they track their health.